Clinical Scorecard: DNA Methylation Biomarker Model in Blood for Predicting Short-term and Long-term Lung Cancer Risk

At a Glance

Key Highlights

• Lung cancer is the most common cancer and leading cause of cancer mortality globally (source needed).
• Screening with low-dose computed tomography (LDCT) reduces lung cancer mortality (source needed).
• Up to 25% of lung cancer cases occur in lifelong never smokers (source needed).
• A model based on DNA methylation can predict lung cancer risk in diverse populations (source needed).
• The study utilized data from the ESTHER and HUNT cohorts for model validation (source needed).

Guideline-Based Recommendations

Diagnosis

• Incorporate molecular biomarkers for personalized risk stratification (source needed).

Management

• Consider lifestyle changes and targeted surveillance for high-risk individuals (source needed).

Monitoring & Follow-up

• Regular follow-up and assessment of lung cancer risk in identified individuals (source needed).

Risks

• Potential harms of lung cancer screening are still debated (source needed).

Patient & Prescribing Data

Personalized interventions based on risk assessment using DNA methylation biomarkers (source needed).

Clinical Best Practices

• Utilize comprehensive health screening and questionnaires for risk assessment (source needed).
• Link cancer registry data for accurate incidence tracking (source needed).
• Ensure informed consent and ethical approval for participant involvement (source needed).

Related Resources & Content

• Cochrane meta-analysis on LDCT screening
• ESTHER study details
• HUNT study details